-
Mashup Score: 18Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer - 11 month(s) ago
Background: Parallel panel germline and somatic genetic testing of all patients with ovarian cancer (OC) can identify more pathogenic variants (PVs) that would benefit from PARP inhibitor (PARPi) therapy, and allow for precision prevention in unaffected relatives with PVs. In this study, we estimate the cost-effectiveness and population impact of parallel panel germline and somatic BRCA testing of all patients with OC incorporating PARPi therapy in the United Kingdom and the United States compared with clinical criteria/family history (FH)–based germline BRCA testing. We also evaluate the cost-effectiveness of multigene panel germline testing alone. Methods: Microsimulation cost-effectiveness modeling using data from 2,391 (UK: n=1,483; US: n=908) unselected, population-based patients with OC was used to compare lifetime costs and effects of panel germline and somatic BRCA testing of all OC cases (with PARPi therapy) (strategy A) versus clinical criteria/FH-based germline BRCA testing
Source: jnccn.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 18Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer - 11 month(s) ago
Background: Parallel panel germline and somatic genetic testing of all patients with ovarian cancer (OC) can identify more pathogenic variants (PVs) that would benefit from PARP inhibitor (PARPi) therapy, and allow for precision prevention in unaffected relatives with PVs. In this study, we estimate the cost-effectiveness and population impact of parallel panel germline and somatic BRCA testing of all patients with OC incorporating PARPi therapy in the United Kingdom and the United States compared with clinical criteria/family history (FH)–based germline BRCA testing. We also evaluate the cost-effectiveness of multigene panel germline testing alone. Methods: Microsimulation cost-effectiveness modeling using data from 2,391 (UK: n=1,483; US: n=908) unselected, population-based patients with OC was used to compare lifetime costs and effects of panel germline and somatic BRCA testing of all OC cases (with PARPi therapy) (strategy A) versus clinical criteria/FH-based germline BRCA testing
Source: jnccn.orgCategories: General Medicine News, Oncologists2Tweet-
https://t.co/1nrL8FzojU Good to see our paper on CE of mainstreaming parallel panel germline and somatic genetic testing out in JNCCN. Panel germline is CE compared to BRCA testing alone. Time to move to panel germline testing in OC. https://t.co/no4cnUoQop
-
-
Mashup Score: 17Human 3D ovarian cancer models reveal malignant cell intrinsic and extrinsic factors that influence CAR T cell activity - 11 month(s) ago
Abstract. In vitro preclinical testing of chimeric antigen receptor (CAR) T cells is mostly carried out in monolayer cell cultures. However, alternative strategies are needed to take into account the complexity and the effects of the tumor microenvironment (TME). Here, we describe the modulation of CAR T cell activity by malignant cells and fibroblasts in human 3D in vitro cell models of increasing complexity. In models combining mucin-1 (MUC1) and TnMUC1 CAR T cells with human high-grade serous ovarian cancer (HGSOC) cell spheroids, malignant cell-intrinsic resistance to CAR T cell killing was due to defective death receptor signaling involving TNFα. Adding primary human fibroblasts to spheroids unexpectedly increased the ability of CAR T cells to kill resistant malignant cells as CCL2 produced by fibroblasts activated CCR2/4+ CAR T cells. However, culturing malignant cells and fibroblasts in collagen gels engendered production of a dense extracellular matrix that impeded CAR T cell a
Source: aacrjournals.orgCategories: General Medicine News, Oncologists2Tweet-
https://t.co/VXK3DtyDVp Delighted to see our paper out - Human 3D ovarian cancer models reveal malignant cell intrinsic and extrinsic factors that influence CAR T cell activity. @ESGO_society @BgcsFellows @wpp_wiph
-
-
Mashup Score: 25
Background: The ovarian cancer(OC) preclinical detectable phase(PCDP), defined as the interval during which cancer is detectable prior to clinical diagnosis, re
Source: papers.ssrn.comCategories: General Medicine News, Oncologists2Tweet-
https://t.co/rGJQL500vY https://t.co/6U0F2L0CPS Delighted to see our pre print out on pre-clinical detectable phase of ovarian cancer & in vivo Tumour doubling time + window for early stage detection. Analysis from UKCTOCS . imp messages for diagnostic pathways & OC screening
-
-
Mashup Score: 24Ovarian cancer: identifying and managing familial and genetic risk—summary of new NICE guidance - 12 month(s) ago
### What you need to know In the UK, around 7500 women are diagnosed with ovarian cancer annually. Approximately 340 000 to 440 000 UK women carry a pathogenic variant in a high risk gene that increases their risk of developing the disease.1 However, only around 3% of people with a high risk gene know that they carry it.2 Most ovarian cancers associated with high risk genes are diagnosed at advanced stage, leading to poor clinical outcomes. Genetic testing can identify at-risk carriers, who can opt for preventive measures such as risk reducing surgery, which significantly lowers the risk of developing ovarian cancer.3 This article summarises new guidance by the National Institute for Health and Care Excellence (NICE) on identifying and managing familial and genetic risk of ovarian cancer.4 It covers select recommendations of relevance to those working in primary care and providers who refer to specialist services. Recommendations from this guideline are for anyone who has an increased
Source: www.bmj.comCategories: General Medicine News, Oncologists2Tweet-
https://t.co/rkCQadIYsH Delighted to see our NICE Guideline on Familial ovarian cancer out in the BMJ. Lots of important new guidance. Helpful for health professionals and patients. @QMUL_WIPH @QMUL_CCSPED @QMUL_WIPH_CPDD @QMBCI @Barts_Charity @NHSBartsHealth @eveappeal
-
-
Mashup Score: 9Outcomes of minimal access retroperitoneal para-aortic lymphadenectomy in patients with locally advanced cervical cancer - 12 month(s) ago
To evaluate outcomes of laparoscopic retroperitoneal para-aortic lymphadenectomy for stage 1b3-3b cervical cancer.Pathology databases searched for all para-aortic lymphadenectomy cases 2005–2016. D…
Source: www.tandfonline.comCategories: General Medicine News, Oncologists2Tweet-
https://t.co/9I3r0Mibu2 Paper out showing Laparoscopic retroperitoneal para-aortic lymphadenectomy is an acceptable procedure which can guide radiotherapy treatment in women with locally advanced cervical cancer. Single centre experience @BgcsFellows @wpp_wiph @ENYGO_official
-
-
Mashup Score: 29Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer - 1 year(s) ago
Background: Parallel panel germline and somatic genetic testing of all patients with ovarian cancer (OC) can identify more pathogenic variants (PVs) that would benefit from PARP inhibitor (PARPi) therapy, and allow for precision prevention in unaffected relatives with PVs. In this study, we estimate the cost-effectiveness and population impact of parallel panel germline and somatic BRCA testing of all patients with OC incorporating PARPi therapy in the United Kingdom and the United States compared with clinical criteria/family history (FH)–based germline BRCA testing. We also evaluate the cost-effectiveness of multigene panel germline testing alone. Methods: Microsimulation cost-effectiveness modeling using data from 2,391 (UK: n=1,483; US: n=908) unselected, population-based patients with OC was used to compare lifetime costs and effects of panel germline and somatic BRCA testing of all OC cases (with PARPi therapy) (strategy A) versus clinical criteria/FH-based germline BRCA testing
Source: jnccn.orgCategories: General Medicine News, Oncologists2Tweet-
https://t.co/ToDE3H5TSH Great to see our paper on cost effectiveness of panel germline and somatic testing in ovarian cancer patients out in JNCCN. Panel germline is cost-effective compared to BRCA testing alone and should replace BRCA testing alone.
-
-
Mashup Score: 9Utility Scores for Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy: Mapping to EQ-5D - 1 year(s) ago
Background: Risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) are the most effective breast and ovarian cancer preventive interventions. EQ-5D is the recommended tool to assess the quality of life and determine health-related utility scores (HRUSs), yet there are no published EQ-5D HRUSs after these procedures. These are essential for clinicians counselling patients and for health-economic evaluations. Methods: We used aggregate data from our published systematic review and converted SF-36/SF-12 summary scores to EQ-5D HRUSs using a published mapping algorithm. Study control arm or age-matched country-specific reference values provided comparison. Random-effects meta-analysis provided adjusted disutilities and utility scores. Subgroup analyses included long-term vs. short-term follow-up. Results: Four studies (209 patients) reported RRM outcomes using SF-36, and five studies (742 patients) reported RRSO outcomes using SF-12/SF-36. RRM is associated with a lo
Source: www.mdpi.comCategories: General Medicine News, Oncologists2Tweet-
Good to see our paper on Utility scores for RRM & RRSO based on mapping to EQ5D published. First utility scores sourced directly from patients undergoing these procedures. helpful for doctors counselling pts about cancer prevention and to researchers. https://t.co/Jx1SauQFAI
-
-
Mashup Score: 9BRCA awareness and testing experience in the UK Jewish population: a qualitative study - 1 year(s) ago
Background 1 in 40 UK Jewish individuals carry a pathogenic variant in BRCA1/BRCA2 . Traditional testing criteria miss half of carriers, and so population genetic testing is being piloted for Jewish people in England. There has been no qualitative research into the factors influencing BRCA awareness and testing experience in this group. This study aimed to explore these and inform improvements for the implementation of population genetic testing. Methods Qualitative study of UK Jewish adults who have undergone BRCA testing. We conducted one-to-one semistructured interviews via telephone or video call using a predefined topic guide, until sufficient information power was reached. Interviews were audio-recorded, transcribed verbatim and interpreted using applied thematic analysis. Results 32 individuals were interviewed (28 carriers, 4 non-carriers). We interpreted five themes intersecting across six time points of the testing pathway: (1) individual differences regarding personal/family
Source: jmg.bmj.comCategories: General Medicine News, Oncologists2Tweet-
https://t.co/6WeG7eNaGG good to see our paper out on 'clinical' J BRCA testing experiences. Carriers want info & support services tailored to individual circumstances. need to inc UK J community BRCA awareness & highlight personal relevance of testing. https://t.co/n3tCtjk4nc
-
-
Mashup Score: 9Utility Scores for Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy: Mapping to EQ-5D - 1 year(s) ago
Background: Risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) are the most effective breast and ovarian cancer preventive interventions. EQ-5D is the recommended tool to assess the quality of life and determine health-related utility scores (HRUSs), yet there are no published EQ-5D HRUSs after these procedures. These are essential for clinicians counselling patients and for health-economic evaluations. Methods: We used aggregate data from our published systematic review and converted SF-36/SF-12 summary scores to EQ-5D HRUSs using a published mapping algorithm. Study control arm or age-matched country-specific reference values provided comparison. Random-effects meta-analysis provided adjusted disutilities and utility scores. Subgroup analyses included long-term vs. short-term follow-up. Results: Four studies (209 patients) reported RRM outcomes using SF-36, and five studies (742 patients) reported RRSO outcomes using SF-12/SF-36. RRM is associated with a lo
Source: www.mdpi.comCategories: General Medicine News, Oncologists2Tweet-
Good to see our paper on Utility scores for RRM & RRSO based on mapping to EQ5D published. First utility scores sourced directly from patients undergoing these procedures. helpful for doctors counselling pts about cancer prevention and to researchers. https://t.co/Jx1SauQFAI
-
https://t.co/1nrL8FzojU Good to see our paper on CE of mainstreaming parallel panel germline and somatic genetic testing out in JNCCN. Panel germline is CE compared to BRCA testing alone. Time to move to panel germline testing in OC. https://t.co/no4cnUoQop